-+ 0.00%
-+ 0.00%
-+ 0.00%

LEADS BIOLABS’ OPAMTISTOMIG (PD-L1/4-1BB BISPECIFIC ANTIBODY) COMPLETES PATIENT ENROLLMENT IN PHASE II STUDY FOR BILIARY TRACT CANCER, FURTHER DEMONSTRATING BREAKTHROUGH POTENTIAL IN IMMUNE-COLD TUMORS

Reuters·07/30/2026 10:36:28

Please log in to view news